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Background: Even on optimal therapy, many patients with heart failure and atrial fibrillation 
experience cardiovascular complications. Additional treatments are needed to reduce these 
events, especially in patients with heart failure and preserved left ventricular ejection fraction 
(HFpEF).  
Methods: This prespecified subanalysis of the randomized EAST – AFNET 4 trial assessed the 
effect of systematic, early rhythm control therapy (ERC; using antiarrhythmic drugs or catheter 
ablation) compared to usual care (UC, allowing rhythm control therapy to improve symptoms) 
on the two primary outcomes of the trial and on selected secondary outcomes in patients with 
heart failure, defined as heart failure symptoms NYHA II-III or left ventricular ejection fraction 
[LVEF] <50%.  
Results: This analysis included 798 patients (300 (37.6%) female, median age 71.0 [64.0, 76.0] 
years, 785 with known LVEF). The majority of patients (n=442) had HFpEF (LVEF≥50%; mean 
LVEF 61% ± 6.3%), the others had heart failure with mid-range ejection fraction (n=211; 
LVEF40-49%; mean LVEF 44% ± 2.9%) or heart failure with reduced ejection fraction (n=132; 
LVEF<40%; mean LVEF 31% ± 5.5%). Over the 5.1-year median follow-up, the composite 
primary outcome of cardiovascular death, stroke or hospitalization for worsening of heart failure 
or for acute coronary syndrome occurred less often in patients randomized to ERC (94/396; 5.7 
per 100 patient-years) compared with patients randomized to UC (130/402; 7.9 per 100 patient-
years; hazard ratio 0.74 [0.56-0.97], p=0.03), not altered by heart failure status (interaction p-
value=0.63). The primary safety outcome (death, stroke, or serious adverse events related to 
rhythm control therapy) occurred in 71/396 (17.9%) heart failure patients randomized to ERC 
and in 87/402 (21.6%) heart failure patients randomized to UC (hazard ratio 0.85 [0.62-1.17], 
p=0.33). LV ejection fraction improved in both groups (LVEF change at two years: ERC 
5.3%±11.6%, UC 4.9%±11.6%, p=0.43). ERC also improved the composite outcome of death or 
hospitalization for worsening of heart failure. 
Conclusions: Rhythm control therapy conveys clinical benefit when initiated within one year of 
diagnosing atrial fibrillation in patients with signs or symptoms of heart failure.  
Clinical Trial Registration: Unique Identifiers: ISRCTN04708680, NCT01288352, 
EudraCT2010-021258-20, Study web site www.easttrial.org; URLs: www.controlled-
trials.com; https://clinicaltrials.gov; https://www.clinicaltrialsregister.eu 
Key Words: atrial fibrillation; rhythm control; controlled trial; heart failure; atrial fibrillation 
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Non-standard Abbreviations and Acronyms  
EAST – AFNET4 Early treatment of atrial fibrillation for stroke prevention trial 
ERC   Early rhythm control 
HFpEF  Heart Failure with preserved ejection fraction 
HFmEF  Heart Failure with mid-range ejection fraction 
HFrEF  Heart Failure with reduced ejection fraction 










What is new? 
• This prespecified subanalysis of the randomized EAST-AFNET 4 trial demonstrates that 
systematic, early rhythm control therapy using antiarrhythmic drugs and atrial fibrillation 
ablation is safe and reduces cardiovascular outcomes in patients with atrial fibrillation 
and heart failure compared with the current strategy of delayed, symptom-directed 
rhythm control. 
• The clinical benefit of early rhythm control therapy was observed in patients with 
preserved, mid-range and reduced left ventricular ejection fraction.  
• Early rhythm control therapy was delivered using a combination of antiarrhythmic drugs 
and AF ablation within guideline recommendations. 
• Left ventricular function, symptoms, and quality of life improved equally in both 
treatment strategies. 
 
What are the clinical implications? 
• Our study supports a treatment strategy of rhythm control therapy (with antiarrhythmic 
drugs or AF ablation) within a year of diagnosing atrial fibrillation in patients with signs 











Atrial fibrillation and heart failure are two associated, common cardiovascular diseases.1 
Approximately 30% of patients with atrial fibrillation also have heart failure.2-4 The sequence of 
presentation varies, but patients with both conditions are at particular risk of cardiovascular 
complications,5, 6 including all-cause and cardiovascular death,5, 7 stroke, and worsening of heart 
failure8 across the spectrum of left ventricular functions.7, 8 Several smaller studies evaluated 
whether rhythm control therapy using atrial fibrillation ablation can improve outcomes in 
patients with atrial fibrillation and heart failure with severely reduced ejection fraction, providing 
homogeneous data demonstrating improved left ventricular function9, 10 and a signal for better 
outcomes.11 These findings led to an increased use of rhythm control therapy, often atrial 
fibrillation ablation, in patients with heart failure and reduced ejection fraction.12,13  Whereas the 
majority of these trials used catheter ablation to deliver rhythm control therapy, the EAST – 
AFNET 4 trial recently demonstrated a clinical benefit of early rhythm control therapy using a 
combination of antiarrhythmic drugs and atrial fibrillation ablation.14 It is less clear whether 
rhythm control therapy conveys clinical benefit in patients with moderately reduced or preserved 
left ventricular ejection fraction.15 Whether the clinical benefit of the EAST-AFNET4 trial can 
be transferred to patients with stable heart failure, especially patients with HFpEF, and whether 
the beneficial effects found using atrial fibrillation ablation in patients with reduced ejection 
fraction can be replicated by early rhythm control using either antiarrhythmic drugs or atrial 
fibrillation ablation, is not known. 
 
Methods 









conducted as an international, investigator-initiated, parallel-group, randomized, open, blinded 
outcome-assessment trial.16 Access to the data will be made available upon request. Please 
contact info@kompetenznetz-vorhofflimmern.de. The EAST – AFNET4 trial protocol was 
approved by ethical review boards for all institutions including approval for the analyses outlined 
in its statistical analysis plan. All participants gave informed consent. 
Trial population and trial intervention 
The EAST-AFNET4 trial enrolled adults with early atrial fibrillation, defined as atrial fibrillation 
diagnosed ≤ 12 months before enrollment. For inclusion, patients were required to be either older 
than 75 years of age, had a previous transient ischemic attack or stroke or met two of the 
following criteria: age > 65 years, female sex, heart failure, hypertension, diabetes mellitus, 
severe coronary artery disease, chronic kidney disease (Modification of Diet in Renal Disease 
stage 3 or 4 [glomerular filtration rate 15 - 59 ml /1.73 m2 of body-surface area]16), and left 
ventricular hypertrophy (diastolic septal wall width, >15 mm). Overall, 2789 patients were 
randomized in a 1:1 fashion to be treated by early rhythm control (n=1395) or usual care 
(n=1394).14 In the early rhythm control group, antiarrhythmic drug therapy, atrial fibrillation 
ablation or cardioversion were required to be initiated early after randomization.  
In patients randomized to usual care the initial treatment consisted of rate-control therapy 
without rhythm-control therapy. Rhythm-control was used only for symptom-restricted rhythm 
control therapy, that is, to treat uncontrolled atrial fibrillation–related symptoms despite adequate 
rate-control.14 
Heart failure subgroup analysis and outcomes 
For this pre-specified subgroup analysis, all patients with signs or symptoms of heart failure at 









left ventricular dysfunction were defined as symptoms according to NYHA class II-III and/or left 
ventricular ejection fraction <50%. Patients were stratified according to baseline left ventricular 
ejection fraction into patients with reduced ejection fraction (HFrEF, left ventricular ejection 
fraction <40%), moderately reduced ejection fraction (HFmrEF, left ventricular ejection fraction 
40-49%) and preserved ejection fraction (HFpEF, left ventricular ejection fraction ≥50%). The 
effects of early rhythm control and usual care between randomized groups [intention to treat 
(ITT analysis)] were compared in patients with heart failure as a whole and categorized by left 
ventricular function. Effects on the first primary outcome (composite of death from 
cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary 
syndrome), the second primary outcome (number of nights spent in the hospital per year), and 
key secondary outcomes (heart rhythm, left ventricular ejection fraction, quality of life, atrial 
fibrillation related symptoms and cognitive function) of the EAST-AFNET4 trial14 were 
analyzed. Furthermore, the primary safety outcome, a composite of death from any cause, stroke, 
or prespecified serious adverse events was evaluated.  
In addition, a “CASTLE-AF like” outcome of death or hospitalization for worsening of 
heart failure according to the primary outcome of the CASTLE-AF trial11 as well as a 
“CABANA-like” composite outcome of death, disabling stroke, serious bleeding or cardiac 
arrest according to the outcome of the CABANA trial17 were analyzed. Both were calculated 
using the correlating defined outcomes of the EAST-AFNET4 trial as assessed by the EAST-
AFNET4 endpoint review committee14. 
Statistical analyses 









Continuous variables are described by mean and standard deviation or median, 1st and 3rd 
quantile. Categorical data are summarized as absolute and relative frequencies. 
The first primary and second primary outcomes of the overall EAST-AFNET4 trial were 
pre-specified for this analysis. For the analysis of the first primary outcome, a Cox proportional 
hazards model with a frailty, i.e. gamma distributed random effect, for the cluster center was 
applied. This model was also used for the analysis of further time-to-event outcomes, i.e. time to 
cardiovascular death, time to first stroke, time to first hospitalization for worsening heart failure, 
time to first hospitalization for acute coronary syndrome, time to all-cause death, time to the 
primary safety outcome, a composite of all-cause death and hospitalization for worsening heart 
failure, as well as a composite of all-cause death, major bleeding, or ischemic stroke with a 
Rankin Score ≥2. The Aalen-Johansen estimator for estimating cumulative incidences was used 
to account for the competing event “all-cause death” within the primary outcome analysis. 
Kaplan-Meier based cumulative incidences were used if all-cause death was a component of the 
outcome. 
The second primary outcome was calculated as the observed sum of nights in the hospital 
divided by the individual follow-up time (in days; in the case of a follow-up time of 0 days, 0.01 
days of follow-up was assumed) and was analyzed using a mixed negative binomial model. This 
model was also used for the analyses of number of hospitalizations. 
Baseline-adjusted mixed linear models were used for continuous secondary outcomes, i.e. 
left ventricular ejection fraction change (baseline to 24 month), change in EQ-5D, change in SF-
12 (Mental and Physical Score), change in Montreal Cognitive Assessment (MoCA) score. A 









Sinus rhythm and symptoms at 24 months were analyzed using mixed logistic models. 
Ordered logistic mixed models were used to analyze improvement in EHRA score and NYHA 
class from baseline to 24 months. 
To analyze whether catheter ablation had an impact on time-to-event outcomes, a time-
varying covariate was used for catheter ablation, i.e. the group changed if catheter ablation was 
observed prior to the first event within the primary outcome. The same holds for other outcomes, 
where only the ablation is counted that was observed before the outcome. 
Safety outcomes were analyzed via chi square test. Multivariable regression was applied to gain 
adjusted effects. An interaction term between treatment group and heart failure was considered in 
the models. 
Subgroup analysis was conducted in the same manner as for the first primary outcome 
but additionally included a corresponding interaction term between treatment group and 
subgroup of interest. Analysis for multivariable models and secondary outcomes within linear or 
(ordered) logistic models are based on multiple imputed baseline data with 60 imputations to 
replace missing values for continuous outcomes and covariates defined for adjustment (see more 
details in the main paper/supplement of the main paper).14 All effects, i.e. mean differences or 
ratios, are given with corresponding 95% confidence intervals. Due to the explorative design of 
the study no adjustment for multiple testing was conducted, i.e. p-values are descriptive. Statistic 
software R Version 4.0.3. was used. 
 
Results 
EAST-AFNET4 randomized 798 patients with stable heart failure, including 442 (56.3%) 









Baseline left ventricular ejection fraction was missing in 13 patients and imputed for the analysis 
(Figure 1). Patient characteristics were not different between randomized groups (Table 1). 
Patient characteristics as per left ventricular ejection fraction subgroup are listed in Table 1 and 
Supplementary Table I. Follow-up was available in all patients. The primary outcome occurred 
in 94/396 patients randomized to early rhythm control and in 130/402 patients randomized to 
usual care (univariable hazard ratio (HR) 0.74 [95% CI 0.56, 0.97], p=0.03; Table 2 and Figure 
2): The effect was not different to the treatment effect in patients with normal left ventricular 
function and without signs of heart failure (HR 0.81 [0.66, 1.01], p=0.06; interaction p (between 
treatment and heart failure)=0.63). Patients with and without ischemic cardiomyopathy had a 
similar risk for the first primary and the second primary outcome; also, changes in left 
ventricular function occurred with comparable incidence for both groups (Supplementary Table 
II). Patients with preserved left ventricular ejection fraction had a lower risk for the first primary 
outcome compared with patients with reduced left ventricular ejection fraction (reduced vs 
preserved HR 1.76 [1.19, 2.59]).  Patients with preserved and mid-range left ventricular ejection 
fraction had a similar risk for the first primary outcome (mid-range vs preserved HR 1.01 [0.68, 
1.50]). Total nights spent in hospital were higher in patients randomized to early rhythm control 
compared with usual care (8.36±27.85 versus 7.46±23.9, univariable treatment effect 1.28 [1.01, 
1.62]; p=0.04; Table 2; Supplementary Figure I; for non-heart failure: 1.00 [0.86, 1.17]; p=0.96; 
interaction p=0.11). Secondary outcomes were observed as depicted in Table 2. Subgroup 
analysis is shown in Supplementary Figure II.     
Outcomes based on the CASTLE-AF and CABANA trials 
Early rhythm control also improved a combined outcome of death or hospitalization for 









experienced a combined outcome of death or hospitalization for worsening of heart failure 
compared with 123/402 patients with events in those randomized to usual care (p=0.04; 
Supplementary Figure III; treatment group-HF interaction p=0.49). The composite outcome of 
death, disabling stroke, serious bleeding or cardiac arrest was numerically lower in patients 
randomized to early rhythm control (51/396 patients with event) than in those randomized to 
usual care (71/402 patients with event), without significant inter-group difference (p=0.10; 
Supplementary Table III and Figure IV; treatment group-HF interaction p=0.32). 
Rhythm control therapy 
Rhythm control therapy was initiated in the majority of patients (367/391, 93.9%), Figure 1) 
randomized to early rhythm control and was prescribed only in a minority of patients in the usual 
control arm (23/394, 5.8%, Figure 1) at randomization. The difference remained substantial after 
2 years (early rhythm control 252/351, 71.8%; usual care 69/352, 19.6%, Figure 1). Most 
patients randomized to early rhythm control received flecainide, dronedarone or amiodarone 
(Figure 1 and Supplementary Table IV). Sinus rhythm at baseline was recorded more often in 
patients with early rhythm control than in patients with usual care (Table 1) and was not 
associated with better outcome for both primary outcomes within multivariable analysis. Based 
on resting-ECG evaluation at 12 and 24 months, sinus rhythm was observed more often in the 
early rhythm control group (Supplementary Figure V). Catheter ablation was performed in 140 
patients with heart failure including 88 patients randomized to early rhythm control and 52 
patients randomized to usual care. Characteristics and distribution of patients treated with or 
without catheter ablation are shown in Supplementary Table V and Figure VI. The effect of early 
rhythm control did not differ between patients treated with atrial fibrillation ablation and patients 









excess of first primary outcomes in the subgroup of patients with HFpEF. The tabulated 
outcomes suggest numerically more early heart failure events in patients treated with amiodarone 
(Table 3). 
Safety outcome 
There were no significant differences between early rhythm control and usual care for the 
primary safety outcome (Table 4 and Supplementary Table VI). 
Improvement of left ventricular ejection fraction 
Left ventricular ejection fraction improved in both groups, resulting in similar improvement of 
left ventricular ejection fraction in patients randomized to early rhythm control or to usual care 
(mean improvement in left ventricular ejection fraction 5.3%±11.6 vs. 4.9%±11.6, respectively; 
univariable p=0.43; Table 2; interaction p-value (between treatment group and HF)=0.38).  Left 
ventricular ejection fraction improved mainly in patients with reduced or mid-range left 
ventricular ejection fraction (Figure 3 and Supplementary Figure VII) without differences 
between randomized groups. A complete recovery of initially reduced left ventricular ejection 
fraction was observed in 24 patients randomized to early rhythm control and in 26 patients 
randomized to usual care, whereas an increase of left ventricular ejection fraction above the 
recommended threshold for ICD-implantation (35%) occurred in 24 patients of the early rhythm 
control group and in 29 patients treated with usual care (Supplementary Table VII).  Sensitivity 
analysis using only complete cases did not show significant differences when compared with 
imputed data (mean improvement in left ventricular ejection fraction early rhythm control 











Symptoms and quality of life 
At the end of the follow-up, a similar number of patients without atrial fibrillation-related 
symptoms were seen in the early rhythm control and the usual care arm (early rhythm control 
226 (69.54%), usual care 214 (64.65%)) and similar outcomes regarding quality of life (EQ-5D 
early rhythm control -2.2±24.3 vs. usual care -4.3±25.6) were observed (Table 2). Atrial 
fibrillation symptoms improved at 24 months in both randomized groups (early rhythm control 
56.4%; usual care 54.2%, Supplementary Table IX and X) without inter-group differences.  
Anticoagulation and heart failure therapy 
The vast majority of patients (around 90%) received guideline-recommended oral 
anticoagulation throughout the follow-up without differences between both groups. Vitamin-K-
antagonists and the novel oral anticoagulants were evenly distributed (Supplementary Table XI). 
Therapy of concomitant cardiovascular conditions appeared well balanced, and a normal blood 
pressure throughout follow-up was seen in both groups (Supplementary Figure VIII). Heart 
failure medication did not show differences between randomized groups at discharge, including 
high use of betablockers (79.1%; early rhythm control 78.4%, usual care 79.9%), ACE or 
angiotensin II receptor blockers (62.5%; early rhythm control 60.1%, usual care 64.9%) or 
diuretics (50.4%; early rhythm control 49.7%, usual care 51.0%, Supplementary Table XII and 
XIII). Mineral corticoid receptor antagonist use was not as high as recommended, but similar 
between randomized groups (overall 12.4 %; early rhythm control 13.7%; usual care 11.2%) 
Digitalis glycoside use at discharge was higher in the usual care group (usual care 9.7%; early 
rhythm control 5.8%), but was not associated with worse outcomes (Supplementary Table XIV 










Rate control therapy 
Rate control therapy as the mainstay of usual care was initiated in 366 patients resulting in a 
well-controlled median heart rate of 65.5 beats/min. in the usual care group. Importantly, rate 
control therapy was given in addition to rhythm control in 85.1% (337) of patients randomized to 
early rhythm control, mainly using betablockers (78.4%) (Figure 1; Supplementary Table XIII 
and Table XVI).  
Outcomes according to NYHA class 
Within multivariable analysis, NYHA class at baseline showed some association with primary 
and secondary outcomes, i.e. NYHA II or III compared with asymptomatic heart failure. NYHA 
classes II and III were not related to left ventricular ejection fraction changes (Supplementary 
Figure XVI). Changes in NYHA class for patients with early rhythm control and usual care are 
visualized in Figure 3. Heart failure symptoms estimated by NYHA class improved after 24 
months in both groups (early rhythm control 53.2%, usual care 45.3%) with a slightly higher 
improvement in patients randomized to early rhythm control (p=0.05; Table 2). The highest 
improvement in NYHA class occurred in patients with preserved ejection fraction 
(Supplementary Table VII). 
Multivariable analysis 
Adjusted effects associated with the first primary outcome were observed for sex (female vs. 
male HR 0.65 (0.47 to 0.89), ejection fraction (reduced left ventricular ejection fraction vs. 
preserved left ventricular ejection fraction HR 1.76 (1.48 to 2.10) and NYHA class II (NYHA 
class II vs. no heart failure HR 2.31 (1.31 to 4.07), and NYHA class III (NYHA class III vs. no 










Complete case analysis 
A complete case analysis of EAST-AFNET4 heart failure patients for secondary outcomes where 




This analysis demonstrates, that early rhythm control therapy reduces a composite of 
cardiovascular death, stroke or hospitalization for worsening of heart failure or for acute 
coronary syndrome compared with usual care (including rhythm control use to improve AF-
related symptoms) in patients with signs or symptoms of heart failure. A similar clinical benefit 
of early rhythm control was found when a “CASTLE-AF like” outcome was calculated, 
extending the clinical benefit found in that study to an unselected cohort of heart failure patients 
with reduced and preserved ejection fraction receiving rhythm control therapy using either 
antiarrhythmic drugs or AF ablation. Unlike CASTLE-AF, the clinical benefit of early rhythm 
control was achieved using antiarrhythmic drugs or AF ablation, chosen by the site investigators 
within guideline recommendations. The majority of patients in this analysis presented with heart 
failure with preserved ejection fraction, similar to the recently published subanalysis of the 
CABANA trial comparing catheter ablation and antiarrhythmic drug therapy in patients with 
atrial fibrillation and heart failure.18 The clinical benefit of early rhythm control was not 
associated with improved left ventricular ejection fraction at two years compared with usual care.  
Strengths of the analysis are the long median follow-up duration of 5.1-years and enrolment of a 










Type of rhythm control therapy 
The majority of patients were treated with antiarrhythmic drugs, with amiodarone (in HFrEF19), 
and flecainide, dronedarone or amiodarone (in HFpEF, Figure 1) as the main agents. 
Antiarrhythmic drugs were prescribed according to the current guidelines and at the 
recommended dose.12,13 Approximately 17% of patients randomized to early rhythm control were 
treated with atrial fibrillation ablation in the first two years after randomization. This suggests 
that the clinical benefit found in this subanalysis can be achieved using antiarrhythmic drugs as 
initial therapy. It is worthwhile to note that flecainide was used in a relatively high number of 
patients without safety concerns. All treatments were given following the guidance of 
international AF guidelines, potentially enabling the safe use of antiarrhythmic drugs in this 
population.  
As expected, patients treated by early rhythm control were more likely to present in sinus 
rhythm at the 24 months follow-up when compared with usual care. Also, the proportion of 
patients with atrial fibrillation at two years was higher in this analysis than in the overall cohort 
of the EAST-AFNET4 trial. This is in line with previously published data,20,14 as heart failure is 
believed to contribute to recurrent atrial fibrillation and to atrial cardiomyopathy21 in patients 
with atrial fibrillation.22 It seems plausible that early initiation of therapy was one of the factors 
that rendered antiarrhythmic drug therapy relatively effective in this analysis. Catheter ablation 
of atrial fibrillation improves quality of life and reduces arrhythmia recurrence to a higher extent 
compared with antiarrhythmic drug therapy, with signals that there may be clinical benefit, 
especially in patients with reduced left ventricular function.20, 23-25 In view of the clinical benefit 
of catheter ablation compared with antiarrhythmic drug therapy seen in the CABANA heart 









could convey even larger clinical benefit than the treatment pattern chosen by the investigators of 
the EAST-AFNET4 trial. Alternatively, antiarrhythmic drugs may be sufficient to achieve early 
rhythm control therapy due to the lower risk of recurrent atrial fibrillation. The value of catheter 
ablation for early rhythm control awaits testing in a controlled clinical trial. 
Timing of rhythm control therapy 
Heart failure patients with atrial fibrillation are at high risk of cardiovascular events including 
cardiovascular death5, 7, stroke, and worsening of heart failure.8 Recent onset atrial fibrillation is 
associated with worse outcomes than established atrial fibrillation.26,2 The early timing of rhythm 
control therapy in this study could have amplified the clinical benefit of early rhythm control 
compared with usual care. It is also possible that the early initiation of rhythm control therapy 
led to an improved efficacy of antiarrhythmic drug therapy as compared with other trials testing 
antiarrhythmic drugs for rhythm control therapy in patients with heart failure.18, 19 
Role of left ventricular function 
Patients with preserved left ventricular ejection fraction had a lower risk for the first primary 
outcome compared with patients with reduced left ventricular ejection fraction. This is in line 
with the findings of several previous studies on patients with reduced ejection fraction and points 
to the fact that left ventricular function retains prognostic importance in patients with heart 
failure and atrial fibrillation.20,23,25 Reduction of cardiovascular events by heart failure therapies 
such as inhibitors of the renin-angiotensin-aldosterone system or cardiac resynchronization 
therapy is accompanied by improvements of cardiac function in patients with heart failure and 
reduced ejection fraction. Early studies found that catheter ablation can improve left ventricular 
function in patients with atrial fibrillation and tachycardiomyopathy.27 The findings of the 









fibrillation resulted not only in better outcomes of the death from any cause or hospitalization for 
worsening heart failure but also in a clinically relevant improvement of left ventricular 
function.20 The present analysis showed a similar clinical benefit of early rhythm control therapy 
which was not accompanied by improved left ventricular ejection fraction at two years compared 
with usual care.  It is possible that rhythm control therapy given to symptomatic patients with 
heart failure and atrial fibrillation led to improved left ventricular function in patients 
randomized to usual care. Exploratory analyses suggest that treatment with amiodarone, but not 
treatment with flecainide, propafenone or dronedarone, was potentially associated with early 
heart failure hospitalizations in patients with heart failure and preserved left ventricular function. 
This is unexpected as amiodarone is considered a safe antiarrhythmic drug in patients with heart 
failure 13,28,29,30 and calls for further clinical research to determine the optimal antiarrhythmic 
drug therapy in patients with heart failure and preserved ejection fraction. 
In summary, this analysis suggests that early rhythm control can prevent clinical 
outcomes in patients with heart failure and that left ventricular function remains a predictor of 
outcomes in patients with heart failure and atrial fibrillation. In addition, sinus rhythm was not 
associated with better primary outcomes. This might at least in part be explained by the fact that 
rhythm control therapy was allowed when symptoms or signs of tachycardiomyopathy occurred 
in the usual care group.  
Heart failure therapy and anticoagulation therapy 
Heart failure patients in the EAST-AFNET4 trial were medically well-treated in both study arms, 
without differences between randomized groups. Treatment included a high use of recommended 
heart failure therapies with betablockers, ACE inhibitors or angiotensin-II receptor antagonists. 









randomized groups. In accordance to the recommendations for heart failure treatment valid at the 
time of recruitment and earlier follow-up period, only a few patients received ARNI, and there 
was no use of SGLT2 inhibitors. These novel drugs for heart failure have shown additional 
benefits including reduced outcomes and improved left ventricular ejection fraction 31,32, yet are 
unlikely to interact with the intervention of the EAST-AFNET4 trial.  
Over 90% of patients with atrial fibrillation and heart failure received oral 
anticoagulation without differences between randomized groups. The majority of patients were 
treated with NOACs. This implicates that oral anticoagulation as a confounder on relevant 
clinical outcomes such as stroke or cardiovascular mortality is unlikely. 
Rate control therapy 
Rate control therapy was delivered as recommended by current guidelines.12,13 Most patients in 
both randomized groups received rate control therapy. The proportion of patients treated with 
selective rate controlling medication was higher in the patients randomized to usual care. When 
the rate controlling effects of antiarrhythmic drugs (amiodarone, dronedarone, propafenone) is 
considered, this difference is smaller. While we cannot exclude a theoretical effect on outcomes 
associated with a more intensive rate control therapy, this is unlikely, in view of the neutral 
outcome of the RACE II trial.33 Besides rate controlling effects of antiarrhythmic drugs, the high 
use of betablocker therapy as a standard of care in heart failure patients explains the high rate of 
prescription of rate controlling therapy in the early rhythm control group.  
Safety aspects 
Both, antiarrhythmic drug therapy and catheter ablation in patients with heart failure and atrial 










Limitations and strengths 
This analysis was prespecified in the statistical analysis plan of the EAST-AFNET 4 trial, but the 
trial was not powered specifically for this subanalysis. EAST-AFNET4 is a strategy trial, the 
intervention was not blinded, and there are no data on left ventricular function or quality of life 
beyond two years of follow-up. Despite these limitations, this analysis reports the first 
contemporary comparison of systematic early rhythm control therapy compared with restricted 
and delayed rhythm control in patients with atrial fibrillation and heart failure. The size of the 
population is larger than most randomized trials published so far, and very comparable to the 
heart failure subanalysis of CABANA. A strength of the analysis is the control group receiving 
treatment according to contemporary atrial fibrillation guidelines.  
Conclusions 
This subanalysis of the EAST – AFNET 4 trial demonstrates that early rhythm control therapy 
using antiarrhythmic drugs or atrial fibrillation ablation is safe and reduces cardiovascular events 
in patients with heart failure. The clinical benefit of early rhythm control is not associated with 
greater improvement in left ventricular ejection fraction compared to that observed with usual 
care. Clinical benefit is observed across the spectrum of heart failure subtypes, suggesting that 
restoring and maintaining sinus rhythm via rhythm control therapy conveys the clinical benefit.  
In the view of the authors, all patients with signs or symptoms of heart failure should be 
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(N=402) Total (N=798) 
Left ventricular ejection fraction at baseline 
categories 
   
   missing variables 5 8 13 
   reduced 57 (14.6%) 75 (19.0%) 132 (16.8%) 
   mid-range 110 (28.1%) 101 (25.6%) 211 (26.9%) 
   preserved 224 (57.3%) 218 (55.3%) 442 (56.3%) 
Left ventricular ejection fraction at baseline 2 
categories 
   
   missing variables 5 8 13 
   <35 35 (9.0%) 47 (11.9%) 82 (10.4%) 
   >=35 356 (91.0%) 347 (88.1%) 703 (89.6%) 
Left ventricular ejection fraction at baseline    
   missing variables 5 8 13 
   means and standard deviation 51.8 (12.4) 50.9 (13.0) 51.4 (12.7) 
   Median (Q1, Q3) 52.0 (44.5, 62.0) 52.0 (41.2, 61.0) 52.0 (43.0, 62.0) 
   range 13.0 - 82.0 18.0 - 85.0 13.0 - 85.0 
Sex    
   Male 240 (60.6%) 258 (64.2%) 498 (62.4%) 
   Female 156 (39.4%) 144 (35.8%) 300 (37.6%) 
Age    
   means and standard deviation 69.5 (9.3) 70.4 (9.0) 69.9 (9.2) 
   Median (Q1, Q3) 70.5 (63.8, 76.0) 72.0 (65.0, 77.0) 71.0 (64.0, 76.0) 
   range 39.0 - 90.0 34.0 - 91.0 34.0 - 91.0 
Body Mass Index (calculated) [kg/m²]    
   missing variables 2 1 3 
   means and standard deviation 29.9 (6.1) 30.1 (5.6) 30.0 (5.9) 
   Median (Q1, Q3) 29.1 (26.1, 32.8) 29.4 (26.2, 33.3) 29.4 (26.2, 33.2) 
   range 16.6 - 58.2 18.1 - 53.3 16.6 - 58.2 
Cardiomyopathy    
   missing variables 2 0 2 
   No 310 (78.7%) 337 (83.8%) 647 (81.3%) 
   Tachycardiomyopathy 25 (6.3%) 12 (3.0%) 37 (4.6%) 
   Hypertrophic cardiomyopathy 4 (1.0%) 3 (0.7%) 7 (0.9%) 
   Dilatative cardiomyopathy 24 (6.1%) 29 (7.2%) 53 (6.7%) 
   Other cardiomyopathy 22 (5.6%) 14 (3.5%) 36 (4.5%) 
   Unknown 9 (2.3%) 7 (1.7%) 16 (2.0%) 
Severe coronary artery disease (previous myocardial 
infarction, CABG or PCI) 
   
   No 308 (77.8%) 311 (77.4%) 619 (77.6%) 
   Yes 88 (22.2%) 91 (22.6%) 179 (22.4%) 
Atrial fibrillation type    
   missing variables 2 0 2 
   First episode 136 (34.5%) 146 (36.3%) 282 (35.4%) 
   Paroxysmal 131 (33.2%) 121 (30.1%) 252 (31.7%) 









Duration of atrial fibrillation history at baseline 
(days) 
   
   missing variables 1 0 1 
   means and standard deviation 73.6 (96.5) 79.4 (176.4) 76.5 (142.5) 
   Median (Q1, Q3) 31.0 (6.0, 109.0) 24.5 (5.0, 99.8) 27.0 (5.0, 102.0) 
   range 0.0 - 639.0 0.0 - 2310.0 0.0 - 2310.0 
CHA2DS2-Vasc Score    
   means and standard deviation 4.0 (1.4) 4.0 (1.4) 4.0 (1.4) 
   Median (Q1, Q3) 4.0 (3.0, 5.0) 4.0 (3.0, 5.0) 4.0 (3.0, 5.0) 
   range 1.0 - 8.0 1.0 - 9.0 1.0 - 9.0 
Overall symptom score (EHRA)    
   missing variables 37 23 60 
   EHRA I (asymptomatic) 81 (22.6%) 88 (23.2%) 169 (22.9%) 
   EHRA II 183 (51.0%) 213 (56.2%) 396 (53.7%) 
   EHRA III 93 (25.9%) 75 (19.8%) 168 (22.8%) 
   EHRA IV 2 (0.6%) 3 (0.8%) 5 (0.7%) 
Heart failure (NYHA classification)    
   missing variables 2 0 2 
   No heart failure 39 (9.9%) 55 (13.7%) 94 (11.8%) 
   I 35 (8.9%) 33 (8.2%) 68 (8.5%) 
   II 255 (64.7%) 259 (64.4%) 514 (64.6%) 
   III 65 (16.5%) 55 (13.7%) 120 (15.1%) 
Prior stroke or transient ischemic attack    
   No 354 (89.4%) 355 (88.3%) 709 (88.8%) 
   Yes 42 (10.6%) 47 (11.7%) 89 (11.2%) 
Arterial hypertension    
   No 44 (11.1%) 58 (14.4%) 102 (12.8%) 
   Yes 352 (88.9%) 344 (85.6%) 696 (87.2%) 
   No 333 (84.1%) 332 (82.6%) 665 (83.3%) 
   Yes 63 (15.9%) 70 (17.4%) 133 (16.7%) 
Heart rhythm    
   missing variables 2 0 2 
   Atrial fibrillation or atrial flutter 217 (55.1%) 237 (59.0%) 454 (57.0%) 
   Sinus rhythm and pacing 177 (44.9%) 165 (41.0%) 342 (43.0%) 
Left ventricular hypertrophy on echocardiography 
(> 15mm wall thickness) 
 
  
  No 384 (97.0%) 388 (96.5%) 772 (96.7%) 
 Yes 12 (3.0%) 14 (3.5%) 26 (3.3%)  
 
  
Systolic LA diameter (maximal diameter) [mm]  
  
missing variables 342 349 691 
means and standard deviation 42.1 (13.9) 43.2 (15.3) 42.6 (14.5) 
Median (Q1, Q3) 43.0 (38.0, 48.8) 43.0 (38.0, 52.0) 43.0 (38.0, 49.5) 
Range 0.0 - 71.0 0.0 - 74.0 0.0 - 74.0  
   
Diastolic LA diameter (maximal diameter) [mm]    
missing variables 77 86 163 
means and standard deviation 45.4 (8.0) 46.0 (9.1) 45.7 (8.5) 









Range 26.0 - 74.0  28.0 - 85.0 26.0 - 85.0  
   
Fractional shortening (calculated) [%]    
missing variables 88 98 186 
means and standard deviation 28.0 (9.9) 29.1 (10.4) 28.5 (10.2) 
Median (Q1, Q3) 27.5 (21.0, 35.0) 29.0 (22.0, 36.0) 28.0 (21.0, 36.0) 
Range 5.0 - 67.0 6.0 - 80.0 5.0 - 80.0  
   
Diabetes    
   missing variables 2 0 2 
   No diabetes or imp. glucose tolerance 281 (71.3%) 300 (74.6%) 581 (73.0%) 
   Yes (managed by diet, oral antidiabetics, and/or 
insulin or no therapy) 
113 (28.7%) 102 (25.4%) 215 (27.0%) 
No clinical characteristics presented in this table demonstrated a statistically significant difference between early rhythm 
control or usual care. Left ventricular function was assessed using two-dimensional quantification based on the Simpson 
method. Left atrial size was determined in M mode. CABG Coronary artery bypass graft; PCI Percutaneous coronary 
intervention; CHA2DS2-VASc score conducted with Congestive Heart failure; EHRA score European Heart Rhythm 
Association score for assessment of atrial fibrillation symptoms; NYHA class New York Heart Association classification of 


















n=402 Treatment effect p-value 
interaction p-
value (treatment 
group and HF) 
First primary outcome patients with 
events/person-years (incidence/100 
person-years) 
94/1649 (5.7) 130/1650 (7.9) 0.74 (0.56 to 0.97) 0.03 0.63 
Death from cardiovascular causes 26/1848 (1.4) 49/1911 (2.6) 0.54 (0.33 to 0.87) 0.011 0.13 
Stroke 8/1827 (0.4) 18/1874 (1.0) 0.46 (0.20 to 1.05) 0.07 0.36 
Hospitalization for worsening of heart 
failure 66/1705 (3.9) 81/1706 (4.7) 0.82 (0.59 to 1.14) 0.24 0.91 
Hospitalization for acute coronary 
syndrome 15/1802 (0.8) 17/1858 (0.9) 0.92 (0.46 to 1.85) 0.83 0.70 
All-cause death 47/1848 (2.5) 65/1911 (3.4) 0.74 (0.50 to 1.08) 0.11 0.39 
All-cause death or Hospitalization for 
worsening of heart failure 
(“CASTLE-AF like outcome”) 
91/1705 (5.3) 123/1706 (7.2) 0.74 (0.56 to 0.98) 0.04 0.49 
Second primary outcome - nights 
spent in hospital/yr 8.36±27.85 7.46±23.90 1.28 (1.01 to 1.62) 0.04 0.11 
Number of hospitalizations/yr 0.96±1.14 0.99±1.44 0.99 (0.76 to 1.19) 0.86 0.74 
Change in left ventricular ejection 
fraction from baseline to 24 months 
5.3±11.6 4.9±11.6 0.57 (-0.84 to 1.98) 0.43 0.54 
Change in EQ-5D score  
(24 months) 
-2.2±24.3 -4.3±25.6 1.89 (-1.76 to 5.54) 0.31 0.59 
Change in SF-12 Mental Score  
(24 months) 
0.2±11.5 2.0±10.8 -1.29 (-2.98 to 0.39) 0.13 0.90 
Change in SF-12 Physical Score  
(24 months) 
0.6±8.7 -0.0±9.4 0.21 (-1.16 to 1.59) 0.76 0.81 
Change in MoCA score  
(24 months) 
-0.1±3.3 0.2±3.3 -0.21 (-0.70 to 0.28) 0.41 0.69 
Sinus rhythm at 24 months— no. of 
patients with feature/total no. (%) 
246/313 (78.59) 175/320 (54.69) 2.97 (2.09 to 4.23) <0.001 0.86 
Asymptomatic at 24 months— no. of 
patients with feature/total no. (%) 
226/325 (69.54) 214/331 (64.65) 1.36 (0.93 to 1.99) 0.17 0.37 
Digoxin at 24 months 12/325 (3.69) 32/331 (9.67) 0.41 (0.20 to 0.84) 0.016 0.85 
NYHA Improved 173/325 (53.2) 150/331 (45.3) p-value mixed ordered logistic 
regression 
0.05 
0.24 NYHA Unchanged 117/325 (36.0) 142/331 (42.9) 
NYHA Worsened 35/325 (10.8) 39/331 (11.8) 
Primary and secondary outcomes observed in patients with heart failure enrolled in the EAST-AFNET4 trial by randomized groups. 
Efficacy outcomes and changes of left ventricular function and NYHA class of the EAST-AFNET4 heart failure population by 
randomized groups. EAST-AFNET4 indicates Early Treatment for Atrial Fibrillation for Stroke Prevention Trial. NYHA class New 
York Heart Association classification of symptoms in heart failure patients. EQ-5D score European Quality of Life 5 Dimensions 










Table 3. Exploratory analysis of primary outcomes within 12 months after randomization in patients randomized to early 
rhythm control, split by planned initial rhythm therapy.  
  
 Planned rhythm control at baseline in patients randomized to early rhythm 
control 
 






moderately or severely 
reduced left ventricular 
function 
3/14 (21.4%) 2/19 (10.5%) 10/81 (12.3%) 0/31 (0.0%) 0/11 (0.0%) 15/156 (9.0%) 
Patients with preserved 
left ventricular function 1/17 (5.9%) 1/20 (5.0%) 8/42 (19.0%) 8/122 (6.6%) 1/10 (10.0%) 20/211 (8.9%) 
The choice of initial rhythm control therapy did not affect early outcomes significantly (p-value for difference in time to first primary 
outcome between planned initial rhythm control therapy p=0.20). Numbers give patients with events / patients in the groups 


















(N=402) Total (N=798) p value 
Occurrence of a primary safety outcome 71 (17.9%) 87 (21.6%) 158 (19.8%) 0.19 
Occurrence of stroke 8 (2.0%) 18 (4.5%) 26 (3.3%) 0.05 
Occurrence of cardiovascular death 26 (6.6%) 49 (12.2%) 75 (9.4%) 0.006 
Occurrence of death 47 (11.9%) 65 (16.2%) 112 (14.0%) 0.08 
Occurrence of a SAE of special interest 20 (5.1%) 10 (2.5%) 30 (3.8%) 0.06 
Occurrence of a SAE of special interest type arrhythmia 12 (3.0%) 6 (1.5%) 18 (2.3%) 0.14 
Occurrence of a SAE of special interest type other 9 (2.3%) 6 (1.5%) 15 (1.9%) 0.42 
Safety outcomes did not differ between randomized groups (results of chi-square test). Numerically there were less events observed 
in the early rhythm control group. SAE Severe adverse event as defined within the EAST-AFNET4 main manuscript 14. EAST-












Figure 1. Consort flow chart of the EAST-AFNET4 heart failure subanalysis. A total of 798 
patients with heart failure were included in this analysis, 396 randomized to early rhythm control 
and 402 randomized to usual care. During follow-up, in the early rhythm control group 201/2049 
total follow-up years were lost (147 follow-up years lost because 31 patients withdrew; 54 
follow-up years lost because 36 patients were lost to follow-up) and 159/2070 total follow-up 
years were lost in the usual care group (108 follow-up years lost because 26 patients withdrew; 
51 follow-up years lost because 33 patients were lost to follow-up). LVEF Left ventricular 
ejection fraction. Screening and randomization are replicated from the main paper.14 
Figure 2. Primary outcome in EAST-AFNET4 heart failure patients by randomized 
groups. Aalen-Johansen Cumulative-Incidence Curves for the effects of early rhythm control on 
the primary outcome. Primary outcome defined as a composite of death from cardiovascular 
causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome. A: 
All patients with heart failure. B: Heart failure with reduced ejection fraction. C: Heart failure 
with mid-range ejection fraction. D: Heart failure with preserved ejection fraction. HFpEF Heart 
failure with preserved ejection fraction; HFmEF Heart failure with mid-range ejection fraction; 
HFrEF Heart failure with reduced ejection fraction. 
Figure 3. Left ventricular function and changes in left ventricular function of EAST-
AFNET4 heart failure patients by randomized groups. Changes in left ventricular ejection 








patients, left) and split by left ventricular ejection fraction groups (reduced, mid-range, and 
preserved). The numerical changes in LVEF, split by randomized group, were early rhythm 
control, reduced LVEF 17.28±13.45; usual care, reduced LVEF 18.10±10.73, mean difference -
0.83 (-4.44 to 2.79, p=0.66); early rhythm control, mid-range LVEF 9.25±10.44; usual care, mid-
range LVEF 8.68±8.97 (mean difference 0.66 (-1.99 to 3.31), p=0.63); early rhythm control, 
preserved LVEF 0.33±8.33; usual care, preserved LVEF -0.93±8.34 (mean difference 0.98 (-0.83 
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